Skip to main content
. 2022 Jun 8;12:816504. doi: 10.3389/fonc.2022.816504

Figure 6.

Figure 6

Metabolic reprogramming from glycolysis to enhanced OXPHOS occurs in drug-resistant cancer cells. This characteristic makes these cells more vulnerable to mitochondria-targeted OXPHOS inhibitors.